» Articles » PMID: 33369661

Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2020 Dec 28
PMID 33369661
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Active surveillance (AS) is now recognized as the preferred management option for most low-risk prostate cancers to minimize risks of overtreatment. Despite increasing use of AS in the US, wide regional variability has been observed, and these regional variations in contemporary practice have not been well described.

Objective: To explore variations between county and Surveillance, Epidemiology, and End Results (SEER) regions in AS in the US.

Design, Setting, And Participants: A cohort study using the SEER Prostate with Watchful Waiting (WW) database linked to the County Area Health Resource File for detailed county-level demographics and physician distribution data was conducted from January 2010 to December 2015. Analysis was performed in October 2020. A total of 79 825 men with clinically localized, low-risk prostate cancer eligible for AS or WW were included.

Exposures: Multiple patient-, county-, and SEER region-level factors, including age, year of diagnosis, county-level densities of urologists, radiation oncologists, primary care physicians, and SEER registry region.

Main Outcomes And Measures: Use of AS or WW as the initial reported treatment strategy were noted. Hierarchical mixed-effect logistic regression models were used to evaluate clustered random regional variation on use of AS or WW. Temporal trends by year in proportions of initial treatment type, as well as county-level local variation, were also estimated.

Results: Of 79 825 men (mean [SD] age, 62.8 [7.6] years, 11 292 [14.1%] non-Hispanic Black, 7506 [9.4%] Hispanic) with low-risk prostate cancer, the mean annualized percent increase in AS rates from 2010 to 2015 ranged from 6.3% in New Mexico to 81.0% in New Jersey. Differences across SEER regions accounted for 17% of the total variation in AS. Increasing age (51-60 years: odds ratio [OR], 1.33; 95% CI, 1.21-1.46; 61-70 years: OR, 1.86; 95% CI, 1.70-2.04; 71-80 years: OR, 2.26; 95% CI, 2.05-2.50) was associated with greater odds of AS. Hispanic ethnicity (OR, 0.79; 95% CI, 0.74-0.85), T category (OR, 0.79; 95% CI, 0.73-0.84), and Medicaid enrollment (OR, 0.73; 95% CI, 0.66-0.81) were associated with lower odds of AS. Black race, county-level socioeconomic factors (household income, educational level, and city type), and specialist densities were not associated with AS use.

Conclusions And Relevance: In this US cohort study based on the SEER-WW database, although the use of AS increased, considerable practice variation appeared to be associated with geographic location, but use of AS was not associated with Black race, specialty professional density, or socioeconomic factors. This small area variation underlies the broader national trends in AS practice and may inform policies aimed at continuing to affect risk-appropriate care for men throughout the US.

Citing Articles

The burden of prostate cancer in the North Africa and Middle East Region from 1990 to 2021.

Safiri S, Shamekh A, Hassanzadeh K, Fazlollahi A, Sullman M, Raeisi M Sci Rep. 2025; 15(1):1853.

PMID: 39805870 PMC: 11731011. DOI: 10.1038/s41598-024-83840-3.


Physician Payment Incentives and Active Surveillance in Low-Risk Prostate Cancer.

Srivastava A, Kaufman S, Shay A, Oerline M, Liu X, Van Til M JAMA Netw Open. 2025; 8(1):e2453658.

PMID: 39775806 PMC: 11795379. DOI: 10.1001/jamanetworkopen.2024.53658.


County-level racial disparities in prostate cancer-specific mortality from 2005 to 2020.

Washington Iii S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J JNCI Cancer Spectr. 2024; 8(6).

PMID: 39495143 PMC: 11631307. DOI: 10.1093/jncics/pkae109.


Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively.

Adetunji A, Venishetty N, Gombakomba N, Jeune K, Smith M, Winer A Curr Urol Rep. 2024; 25(10):253-260.

PMID: 38869692 DOI: 10.1007/s11934-024-01219-3.


Spatial characteristics of non-communicable diseases and their associations to social conditions in a large urban cohort in Germany-Results from the Hamburg City Health Study.

Andrees V, Bei der Kellen R, Augustin M, Gallinat J, Harth V, Hoven H PLoS One. 2024; 19(4):e0301475.

PMID: 38593150 PMC: 11003678. DOI: 10.1371/journal.pone.0301475.


References
1.
Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P . Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden. JAMA Oncol. 2016; 3(10):1393-1398. PMC: 5559339. DOI: 10.1001/jamaoncol.2016.3600. View

2.
Chen R, Rumble R, Loblaw D, Finelli A, Ehdaie B, Cooperberg M . Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016; 34(18):2182-90. DOI: 10.1200/JCO.2015.65.7759. View

3.
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A . Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2009; 28(1):126-31. DOI: 10.1200/JCO.2009.24.2180. View

4.
Auffenberg G, Lane B, Linsell S, Cher M, Miller D . Practice- vs Physician-Level Variation in Use of Active Surveillance for Men With Low-Risk Prostate Cancer: Implications for Collaborative Quality Improvement. JAMA Surg. 2017; 152(10):978-980. PMC: 5831460. DOI: 10.1001/jamasurg.2017.1586. View

5.
Austin P, Merlo J . Intermediate and advanced topics in multilevel logistic regression analysis. Stat Med. 2017; 36(20):3257-3277. PMC: 5575471. DOI: 10.1002/sim.7336. View